A randomized phase II/III trial of 3 weekly intraperitoneal versus intravenous carboplatin in combination with intravenous weekly dose-dense paclitaxel for newly diagnosed ovarian, fallopian tube and primary peritoneal cancer

Keiichi Fujiwara, Eriko Aotani, Tetsutaro Hamano, Shoji Nagao, Hiroyuki Yoshikawa, Toru Sugiyama, Junzo Kigawa, Daisuke Aoki, Noriyuki Katsumata, Masahiro Takeuchi, Mitsuaki Suzuki

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Retrospective studies and a Phase II trial demonstrated the promising efficacy and safety of intraperitoneal administration of carboplatin in ovarian, fallopian tube and primary peritoneal cancer. A Japanese Gynecologic Oncology Group 3016 randomized Phase III trial for these cancers showed dose-dense weekly administration of paclitaxel significant improvement of progression-free survival and overall survival over every 3-week administration. From June 2010, we have been conducting a randomized Phase II/III trial of intravenous versus intraperitoneal administration of carboplatin every 3 week in combination with dose-dense weekly administration of paclitaxel. The purpose of this trial is to prove the superiority of intraperitoneal administration of carboplatin over intravenous administration. Primary endpoint is progression-free survival and secondary endpoints include overall survival, quality of life assessment and cost-benefit. The first 120 patients will be evaluated for the feasibility of intraperitoneal arm and a total of 746 patients will be enrolled in a Phase III study.

Original languageEnglish
Pages (from-to)278-282
Number of pages5
JournalJapanese Journal of Clinical Oncology
Volume41
Issue number2
DOIs
Publication statusPublished - 2011 Feb

Fingerprint

Fallopian Tubes
Carboplatin
Paclitaxel
Disease-Free Survival
Neoplasms
Survival
Intravenous Administration
Cost-Benefit Analysis
Retrospective Studies
Quality of Life
Safety

Keywords

  • Carboplatin
  • Dose-dense chemotherapy
  • Intraperitoneal chemotherapy
  • Ovarian cancer
  • Paclitaxel

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Radiology Nuclear Medicine and imaging

Cite this

A randomized phase II/III trial of 3 weekly intraperitoneal versus intravenous carboplatin in combination with intravenous weekly dose-dense paclitaxel for newly diagnosed ovarian, fallopian tube and primary peritoneal cancer. / Fujiwara, Keiichi; Aotani, Eriko; Hamano, Tetsutaro; Nagao, Shoji; Yoshikawa, Hiroyuki; Sugiyama, Toru; Kigawa, Junzo; Aoki, Daisuke; Katsumata, Noriyuki; Takeuchi, Masahiro; Suzuki, Mitsuaki.

In: Japanese Journal of Clinical Oncology, Vol. 41, No. 2, 02.2011, p. 278-282.

Research output: Contribution to journalArticle

Fujiwara, Keiichi ; Aotani, Eriko ; Hamano, Tetsutaro ; Nagao, Shoji ; Yoshikawa, Hiroyuki ; Sugiyama, Toru ; Kigawa, Junzo ; Aoki, Daisuke ; Katsumata, Noriyuki ; Takeuchi, Masahiro ; Suzuki, Mitsuaki. / A randomized phase II/III trial of 3 weekly intraperitoneal versus intravenous carboplatin in combination with intravenous weekly dose-dense paclitaxel for newly diagnosed ovarian, fallopian tube and primary peritoneal cancer. In: Japanese Journal of Clinical Oncology. 2011 ; Vol. 41, No. 2. pp. 278-282.
@article{15d08733b31544b8883c5c56f332d0ea,
title = "A randomized phase II/III trial of 3 weekly intraperitoneal versus intravenous carboplatin in combination with intravenous weekly dose-dense paclitaxel for newly diagnosed ovarian, fallopian tube and primary peritoneal cancer",
abstract = "Retrospective studies and a Phase II trial demonstrated the promising efficacy and safety of intraperitoneal administration of carboplatin in ovarian, fallopian tube and primary peritoneal cancer. A Japanese Gynecologic Oncology Group 3016 randomized Phase III trial for these cancers showed dose-dense weekly administration of paclitaxel significant improvement of progression-free survival and overall survival over every 3-week administration. From June 2010, we have been conducting a randomized Phase II/III trial of intravenous versus intraperitoneal administration of carboplatin every 3 week in combination with dose-dense weekly administration of paclitaxel. The purpose of this trial is to prove the superiority of intraperitoneal administration of carboplatin over intravenous administration. Primary endpoint is progression-free survival and secondary endpoints include overall survival, quality of life assessment and cost-benefit. The first 120 patients will be evaluated for the feasibility of intraperitoneal arm and a total of 746 patients will be enrolled in a Phase III study.",
keywords = "Carboplatin, Dose-dense chemotherapy, Intraperitoneal chemotherapy, Ovarian cancer, Paclitaxel",
author = "Keiichi Fujiwara and Eriko Aotani and Tetsutaro Hamano and Shoji Nagao and Hiroyuki Yoshikawa and Toru Sugiyama and Junzo Kigawa and Daisuke Aoki and Noriyuki Katsumata and Masahiro Takeuchi and Mitsuaki Suzuki",
year = "2011",
month = "2",
doi = "10.1093/jjco/hyq182",
language = "English",
volume = "41",
pages = "278--282",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - A randomized phase II/III trial of 3 weekly intraperitoneal versus intravenous carboplatin in combination with intravenous weekly dose-dense paclitaxel for newly diagnosed ovarian, fallopian tube and primary peritoneal cancer

AU - Fujiwara, Keiichi

AU - Aotani, Eriko

AU - Hamano, Tetsutaro

AU - Nagao, Shoji

AU - Yoshikawa, Hiroyuki

AU - Sugiyama, Toru

AU - Kigawa, Junzo

AU - Aoki, Daisuke

AU - Katsumata, Noriyuki

AU - Takeuchi, Masahiro

AU - Suzuki, Mitsuaki

PY - 2011/2

Y1 - 2011/2

N2 - Retrospective studies and a Phase II trial demonstrated the promising efficacy and safety of intraperitoneal administration of carboplatin in ovarian, fallopian tube and primary peritoneal cancer. A Japanese Gynecologic Oncology Group 3016 randomized Phase III trial for these cancers showed dose-dense weekly administration of paclitaxel significant improvement of progression-free survival and overall survival over every 3-week administration. From June 2010, we have been conducting a randomized Phase II/III trial of intravenous versus intraperitoneal administration of carboplatin every 3 week in combination with dose-dense weekly administration of paclitaxel. The purpose of this trial is to prove the superiority of intraperitoneal administration of carboplatin over intravenous administration. Primary endpoint is progression-free survival and secondary endpoints include overall survival, quality of life assessment and cost-benefit. The first 120 patients will be evaluated for the feasibility of intraperitoneal arm and a total of 746 patients will be enrolled in a Phase III study.

AB - Retrospective studies and a Phase II trial demonstrated the promising efficacy and safety of intraperitoneal administration of carboplatin in ovarian, fallopian tube and primary peritoneal cancer. A Japanese Gynecologic Oncology Group 3016 randomized Phase III trial for these cancers showed dose-dense weekly administration of paclitaxel significant improvement of progression-free survival and overall survival over every 3-week administration. From June 2010, we have been conducting a randomized Phase II/III trial of intravenous versus intraperitoneal administration of carboplatin every 3 week in combination with dose-dense weekly administration of paclitaxel. The purpose of this trial is to prove the superiority of intraperitoneal administration of carboplatin over intravenous administration. Primary endpoint is progression-free survival and secondary endpoints include overall survival, quality of life assessment and cost-benefit. The first 120 patients will be evaluated for the feasibility of intraperitoneal arm and a total of 746 patients will be enrolled in a Phase III study.

KW - Carboplatin

KW - Dose-dense chemotherapy

KW - Intraperitoneal chemotherapy

KW - Ovarian cancer

KW - Paclitaxel

UR - http://www.scopus.com/inward/record.url?scp=79251635492&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79251635492&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyq182

DO - 10.1093/jjco/hyq182

M3 - Article

C2 - 20937602

AN - SCOPUS:79251635492

VL - 41

SP - 278

EP - 282

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 2

ER -